Join us as we ask questions such as: How do we strengthen the link between a drug and its related adverse events from pre-clinical to post-marketing? What are the core and emerging challenges of adhering to Pharmacovigilance laws and risk management? Can we communicate benefits and risks to patients? How is the EudraVigilance system implemented in the pre and post-marketing approval of medicinal drugs? How can we harmonise coding for EU and US markets?KEY SPEAKERS INCLUDE:Graeme Ladds, CEO, Director of Operations, Pharmacovigilance, PharSafer Associates LtdDr. Pipasha Biswas, Executive Director & QPPV, Symogen LtdJim Slattery, Statistician, Pharmacovigilance, European Medicines Agency (EMA)Dr. Tomas Moraleda , International Medical Officer, MedDRA MSSODoris Irene Stenver, Chief Medical Officer, Danish Health and Medicines Authority, Member of PRACDr. Michael Merz, Chair Investigative Liver Expert Team, Novartis Institutes for Biomedical ResearchShelley Gandhi, Director of Pharmacovigilance and Drug Safety, NDA GroupHIGHLIGHTS FOR 2015EMA KEYNOTE ADDRESS: Risk Management through Statistical IntegrationUnderstand the EU’s harmonisation initiatives through MedDRA and EudravigilanceOptimise the outcome of risk assessments and risk minimisation measuresLearn new PRAC updates for 2015Efficiently bridge preclinical to clinical safety data